NPR News

Lance Armstrong. He has a superhero's name, right out of the comic books. He moved from conquering stages of one kind — bike racing — to stages of another kind — cancer. He's chiseled and driven and known all over the world.

But now we learn that the superhero has given up in one of his biggest battles. He says he will no longer continue to fight charges by the United States Anti-Doping Agency that he used performance enhancing drugs to win bicycle races.

Dispatch formed in 1994, and quickly became a staple of college campuses and summer music festivals across the country. When members Chad Urmston, Brad Corrigan and Pete Heimbold decided to call it quits in 2002, fans knew the band would be missed.

A few years ago, if Bill Graff wanted to find out whether other farmers' fields looked anything like his, he'd make some calls and check an online bulletin board. It might take him a few days, even a week, to get a sense of how his crops stacked up against others in his region.

Now Graff, 53, who grows 1,400 acres of corn, soybean, wheat and hay in central Illinois, checks his Twitter feed. "I can get a half-way decent idea of what's going on out there instantaneously," Graff says.

The Georgia-based rock band Blackberry Smoke has been together for more than a decade, slowly building an audience the old-fashioned way by relentless touring — around 250 shows a year.

A summertime basketball camp can cost a kid several hundred dollars. But the Basketball in the Barrio camp — held just two blocks from the U.S.-Mexico border in El Paso — costs just one buck.

Actually, only a portion of the camp is about basketball, says co-founder Rus Bradburd. The experience is sponsored by Athletes United for Peace, a group that tries to promote peace and harmony through sports.

The head of the United States Anti-Doping Agency says Lance Armstrong knows the truth and he has decided that instead of airing every piece of evidence publicly and in front of an impartial court, the dethroned seven-time Tour de France winner has decided to "hold on to baseless soundbites."

An experimental drug that aimed to slow the development of plaques and help clear them from the brains of Alzheimer's patients failed in two late-stage studies conducted by Eli Lilly & Co., the company said today.